GlobeNewsWire · RHHBY · November 16, 2026
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗